# AbbVie

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/abbvie
Canonical HTML page: https://getfinancebrief.com/entity/abbvie

## Timeline

- **2026-03-03**: TD Cowen Conference — AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
- **2026-02-26**: DOJ Legal Support — The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
- **2026-02-25**: RBC Coverage Launch — RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
- **2023-01-31**: Humira Exclusivity Ends — The first biosimilar for Humira enters the U.S. market, marking the start of the 'Humira cliff'.

## Recent coverage (4 stories)

### IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?
2026-07-19 06:02:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Full story: https://getfinancebrief.com/story/ihe-ixj-healthcare-etf-fee-comparison

### Top Dividend Picks: Analyzing Yield and Stability in a Volatile Market
2026-03-21 21:53:19 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A new screening of high-conviction dividend stocks highlights leaders across healthcare, energy, and technology sectors. As investors seek defensive positioning, these seven companies represent a blend of dividend growth and capital preservation potential.
Full story: https://getfinancebrief.com/story/dividend-stocks-to-watch-march-2026

### RBC Capital Bullish on AbbVie: Initiates Coverage with Outperform Rating
2026-02-27 14:47:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
Full story: https://getfinancebrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

### Genmab Faces Profit Squeeze as R&D for ADC Pipeline Weighs on 2026 Outlook
2026-02-19 08:27:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Full story: https://getfinancebrief.com/story/genmab-q4-2025-earnings-analysis-rd-spending

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.